rs193922103
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_000053.4(ATP7B):āc.2305A>Gā(p.Met769Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000252 in 1,614,022 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M769I) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000053.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP7B | NM_000053.4 | c.2305A>G | p.Met769Val | missense_variant | 8/21 | ENST00000242839.10 | NP_000044.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATP7B | ENST00000242839.10 | c.2305A>G | p.Met769Val | missense_variant | 8/21 | 1 | NM_000053.4 | ENSP00000242839 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152130Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000681 AC: 17AN: 249552Hom.: 0 AF XY: 0.0000517 AC XY: 7AN XY: 135390
GnomAD4 exome AF: 0.000264 AC: 386AN: 1461892Hom.: 0 Cov.: 31 AF XY: 0.000264 AC XY: 192AN XY: 727248
GnomAD4 genome AF: 0.000138 AC: 21AN: 152130Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74318
ClinVar
Submissions by phenotype
Wilson disease Pathogenic:12
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 11, 2020 | The p.Met769Val variant in ATP7B has been identified in the homozygous or compound heterozygous state in at least 6 individuals with Wilson disease (Curtis 1999, Caca 2001, Lepori 2007, Nicastro 2009, Weiss 2010, Moller 2011). It has also been identified in 0.016% (20/128686) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org) and reported in ClinVar (Variation ID 35706). In vitro functional studies support an impact on protein function (Forbes 2000, Huster 2012, ). In addition, computational prediction tools and conservation analyses are consistent with pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Wilson disease. ACMG/AMP criteria applied: PM3_VeryStrong, PM2_Supporting, PP3, PP4, PS3_Supporting. - |
Pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Feb 05, 2024 | This missense variant replaces methionine with valine at codon 769 of the ATP7B protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown conflicting results on this variant's impact on copper transport activity (PMID: 9837819, 10942420, 12557139, 18203200, 17717039, 22240481, 22806248). This variant has been reported in individuals affected with Wilson disease (PMID: 10502777, 11405812, 11690702, 15202786, 17449133, 17949296, 19118915, 20082719, 20517649, 21610751, 23518715, 23982005, 27022412, 27706781, 29321352, 29431110, 31980526, 33159804, 33640437, 34400371). In a number of these individuals, this variant was confirmed to be in the compound heterozygous state (PMID: 29321352, 33159804, 33640437) or the homozygous state (PMID: 19118915, 22806248, 32028086). This variant has been identified in 20/280946 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 03, 2024 | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 769 of the ATP7B protein (p.Met769Val). This variant is present in population databases (rs193922103, gnomAD 0.01%). This missense change has been observed in individual(s) with Wilson disease (PMID: 7626145, 11690702, 19118915, 20517649, 21610751). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 35706). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATP7B protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects ATP7B function (PMID: 9837819, 22240481). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 14, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 11, 2019 | The ATP7B c.2305A>G; p.Met769Val variant (rs193922103) is reported in the literature in the compound heterozygous or homozygous state in multiple individuals affected with Wilson disease (Caca 2001, Curtis 1999, Garcia-Villarreal 2000, Moller 2011, Nicastro 2009, Weiss 2010, Wu 2001). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 35706), and is found in the non-Finnish European population with an allele frequency of 0.016% (20/128,686 alleles) in the Genome Aggregation Database. The methionine at codon 769 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Functional analyses of the variant protein show reduced copper transport activity (Forbes and Cox 1998, Huster 2012). Based on available information, this variant is considered to be pathogenic. References: Caca K et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol. 2001 Nov;35(5):575-81. Curtis D et al. A study of Wilson disease mutations in Britain. Hum Mutat. 1999;14(4):304-11. Forbes JR and Cox DW et al. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet. 1998 Dec;63(6):1663-74. Garcia-Villarreal L et al. High prevalence of the very rare Wilson disease gene mutation Leu708Pro in the Island of Gran Canaria (Canary Islands, Spain): a genetic and clinical study. Hepatology. 2000 Dec;32(6):1329-36. Huster D et al. Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology. 2012 Apr;142(4):947-956.e5. Moller LB et al. Clinical presentation and mutations in Danish patients with Wilson disease. Eur J Hum Genet. 2011 Sep;19(9):935-41. Nicastro E et al. Genotype-phenotype correlation in Italian children with Wilson's disease. J Hepatol. 2009 Mar;50(3):555-61. Weiss KH et al. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S233-40. Wu ZY et al. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. Arch Neurol. 2001 Jun;58(6):971-6. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 20, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 24, 2019 | NM_000053.3(ATP7B):c.2305A>G(M769V) is classified as pathogenic in the context of Wilson disease. Sources cited for classification include the following: PMID 9837819, 19118915, 23518715, 22692182, 24253677, 22240481 and 10942420. Classification of NM_000053.3(ATP7B):c.2305A>G(M769V) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing;curation | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 18, 2011 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 25, 2022 | - - |
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Nov 17, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2023 | ATP7B: PM1, PM2, PM3, PM5, PP3, PS3:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 23, 2024 | Observed multiple times with a second ATP7B pathogenic variant in unrelated patients with Wilson disease referred for genetic testing at GeneDx and in published literature; however, it is not known whether the variants occurred on the same allele (in cis) or on different alleles (in trans) in all cases (PMID: 33159804, 20517649, 21610751); Published functional studies found M769V is associated with significantly reduced copper uptake and decreased thermal stability compared to wildtype (PMID: 22240481, 9837819); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 9311736, 11405812, 19118915, 24253677, 18371106, 21610751, 34400371, 35271763, 9837819, 20517649, 7626145, 11093740, 22692182, 23518715, 10502777, 27022412, 29431110, 17717039, 16939419, 14986826, 11690702, 12557139, 10942420, 29321352, 31980526, 33159804, 27535533, 22240481) - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 15, 2021 | PP3, PM1, PM2, PM5 - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 28, 2016 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 22, 2017 | The p.M769V pathogenic mutation (also known as c.2305A>G), located in coding exon 8 of the ATP7B gene, results from an A to G substitution at nucleotide position 2305. The methionine at codon 769 is replaced by valine, an amino acid with highly similar properties. This mutation was reported in multiple unrelated individuals (Curtis D et al. Hum. Mutat., 1999;14:304-11; García-Villarreal L et al. Hepatology, 2000 Dec;32:1329-36; Caca K et al. J. Hepatol., 2001 Nov;35:575-81; Weiss KH et al. J. Inherit. Metab. Dis., 2010 Dec;33 Suppl 3:S233-40), including two homozygous individuals with hepatic Wilson disease (Nicastro E et al. J. Hepatol., 2009 Mar;50:555-61). Functional studies demonstrated that this mutation impairs the protein function (Forbes JR et al. Am. J. Hum. Genet., 1998 Dec;63:1663-74; Huster D et al. Gastroenterology, 2012 Apr;142:947-956.e5). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at